Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IITreatmentClosed18 and overNCI, Other05-098
MSKCC-05098, NCT00255801

Trial Description


RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and bexarotene, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bexarotene may also cause cutaneous T-cell lymphoma cells to look more like normal cells, and to grow and spread more slowly. Giving liposomal doxorubicin followed by bexarotene may be an effective treatment for cutaneous T-cell lymphoma.

PURPOSE: This phase II trial is studying how well giving liposomal doxorubicin followed by bexarotene works in treating patients with cutaneous T-cell lymphoma.

Further Study Information



  • Determine the progression-free survival of patients with stage IB-IV cutaneous T-cell lymphoma treated with doxorubicin HCl liposome followed by bexarotene.


  • Determine the complete and partial response rate in patients treated with this regimen.

OUTLINE: This is an open-label, multicenter study.

Patients receive doxorubicin HCl liposome IV over 30-90 minutes once on day 1. Treatment repeats every 2 weeks for 8 courses. Beginning within 4 weeks after the last dose of doxorubicin HCl liposome, patients receive oral bexarotene once daily for at least 16 weeks. Patients who achieve a complete or partial response may continue to receive bexarotene in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 5 years.

Eligibility Criteria


  • Histologically confirmed cutaneous T-cell lymphoma
  • Stage IB-IV disease
  • Measurable disease
  • Newly diagnosed or previously treated disease
  • No demonstrated resistance to prior bexarotene


Performance status

  • Karnofsky 60-100%

Life expectancy

  • Not specified


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3


  • AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Bilirubin < 1.5 times ULN


  • Creatinine ≤ 1.5 times ULN


  • Ejection fraction ≥ 50% by MUGA or 2-D echocardiogram
  • No New York Heart Association class II-IV heart disease
  • No clinical evidence of congestive heart failure


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 4 weeks after completion of study treatment
  • No history of hypersensitivity reactions attributed to doxorubicin HCl liposome or its components
  • No active potentially life-threatening infection
  • No other acute disease



  • See Disease Characteristics
  • Prior doxorubicin allowed provided the cumulative dose is ≤ 300 mg/m^2
  • Prior epirubicin hydrochloride allowed provided the cumulative dose is ≤ 540 mg/m^2

Trial Contact Information

Trial Lead Organizations/Sponsors

Memorial Sloan-Kettering Cancer Center

  • National Cancer Institute
  • Tibotec, Incorporated
  • M. D. Anderson Cancer Center at University of Texas
  • NYU Cancer Institute at New York University Medical Center
  • Hackensack University Medical Center Cancer Center
  • Roswell Park Cancer Institute
David J. Straus, MD, Principal Investigator
Steven M. Horwitz, MD, Principal Investigator
Patricia L. Myskowski, MD, Principal Investigator

Link to the current record.
NLM Identifier NCT00255801 processed this data on April 09, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to